Drug Interactions between Folinic-Plus and thiabendazole
This report displays the potential drug interactions for the following 2 drugs:
- Folinic-Plus (multivitamin)
- thiabendazole
Interactions between your drugs
No interactions were found between Folinic-Plus and thiabendazole. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Folinic-Plus
A total of 17 drugs are known to interact with Folinic-Plus.
- Folinic-plus is in the drug class vitamin and mineral combinations.
- Folinic-plus is used to treat Dietary Supplementation.
thiabendazole
A total of 56 drugs are known to interact with thiabendazole.
- Thiabendazole is in the drug class anthelmintics.
- Thiabendazole is used to treat the following conditions:
Drug and food interactions
thiabendazole food
Applies to: thiabendazole
Using caffeine together with thiabendazole can increase the effects of caffeine. Contact your doctor if you experience loss of appetite, sleep problems, stomach pain, a fast heart rate, or a slow heart rate. You may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
thiabendazole food
Applies to: thiabendazole
Consumer information for this interaction is not currently available.
MONITOR: Smoking cessation may lead to elevated plasma concentrations and enhanced pharmacologic effects of drugs that are substrates of CYP450 1A2 (and possibly CYP450 1A1) and/or certain drugs with a narrow therapeutic index (e.g., flecainide, pentazocine). One proposed mechanism is related to the loss of CYP450 1A2 and 1A1 induction by polycyclic aromatic hydrocarbons in tobacco smoke; when smoking cessation agents are initiated and smoking stops, the metabolism of certain drugs may decrease leading to increased plasma concentrations. The mechanism by which smoking cessation affects narrow therapeutic index drugs that are not known substrates of CYP450 1A2 or 1A1 is unknown. The clinical significance of this interaction is unknown as clinical data are lacking.
MANAGEMENT: Until more information is available, caution is advisable if smoking cessation agents are used concomitantly with drugs that are substrates of CYP450 1A2 or 1A1 and/or those with a narrow therapeutic range. Patients receiving smoking cessation agents may require periodic dose adjustments and closer clinical and laboratory monitoring of medications that are substrates of CYP450 1A2 or 1A1.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.